ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 134 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.55 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $35,188,000 | +2.5% | 1,954,904 | 0.0% | 48.80% | +34.1% |
| Q2 2021 | $34,328,000 | -30.3% | 1,954,904 | 0.0% | 36.39% | -15.9% |
| Q1 2021 | $49,264,000 | +369.9% | 1,954,904 | +20.7% | 43.26% | +255.0% |
| Q4 2020 | $10,483,000 | +495.6% | 1,620,244 | +136.6% | 12.18% | +830.2% |
| Q3 2020 | $1,760,000 | -10.3% | 684,912 | +157.8% | 1.31% | +103.1% |
| Q4 2018 | $1,963,000 | -56.7% | 265,694 | -14.9% | 0.64% | -35.6% |
| Q3 2018 | $4,536,000 | -27.3% | 312,368 | 0.0% | 1.00% | -25.5% |
| Q2 2018 | $6,238,000 | +14.0% | 312,368 | 0.0% | 1.34% | +12.6% |
| Q1 2018 | $5,473,000 | +4.2% | 312,368 | +46.7% | 1.19% | -19.1% |
| Q4 2017 | $5,251,000 | -22.6% | 212,950 | -19.0% | 1.47% | -21.1% |
| Q3 2017 | $6,787,000 | +62.6% | 262,950 | +87.8% | 1.87% | +16.7% |
| Q1 2017 | $4,175,000 | -1.3% | 140,000 | -10.1% | 1.60% | -12.8% |
| Q4 2016 | $4,228,000 | – | 155,767 | – | 1.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |